Creative Planning
MNPR icon

Creative Planning’s Monopar Therapeutics MNPR Stock Holding History

Creative Planning’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$719K Buy
7,768
+1,781
+30% +$110K ﹤0.01% 2903
2026
Q1 		$328K Buy
+5,987
New +$362K ﹤0.01% 3357

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Creative Planning's MNPR Position: Q2 2026 in Review

Creative Planning increased its Monopar Therapeutics (MNPR) stake by 30% in Q2 2026, buying an estimated $110K and bringing the position to 7,768 shares worth $719K. The position accounts for ﹤0.01% of the portfolio, ranked #2903.

Creative Planning first reported a position in MNPR in Q1 2026 and has held it in 2 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Creative Planning held 7,768 shares of Monopar Therapeutics worth $719K as of Q2 2026.
  • Creative Planning bought 1,781 Monopar Therapeutics shares in Q2 2026, an estimated $110K.
  • Monopar Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #2903 holding.
  • Creative Planning first reported a position in Monopar Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.